Press Releases Oneness Biotech Co., Ltd.

Equities

4743

TW0004743000

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
158.5 ^TWD	-0.31%		+6.38%	-18.51%

Mar. 29	Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis	CI
Mar. 11	Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oneness Biotech : The Drug Administration of Vietnam has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon	22-07-04	PU
Oneness Biotech : announces the information about the investor's conference of 2022 Q2.	22-06-22	PU
Oneness Biotech : The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations	22-06-02	PU
Oneness Biotech : receives a China patent on antagonistic PDL1 aptamers.	22-05-26	PU
Oneness Biotech : The Annual General Shareholders' Meeting approved the removal of non-competition restriction on the newly-elected director.	22-05-24	PU
Oneness Biotech : By-election of one director of the board in 2022 shareholders' meeting	22-05-24	PU
Oneness Biotech : announce the important resolutions of the 2022 Annual General Shareholders' Meeting	22-05-24	PU
Oneness Biotech : received the notification by the international CRO on the unblinded data of FB825 Phase 2a study in moderate-to-severe atopic dermatitis in the U.S.	22-05-02	PU
Oneness Biotech : The Food and Drug Administration–Philippines (PFDA) has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon	22-04-18	PU
Oneness Biotech : has been invited to present at the "11th Taiwan CEO Week" online investor's conference co-organized by TWSE and QIC	22-04-11	PU
Oneness Biotech : receives ISO13485 Medical Devices Quality Management System Certificate.	22-04-08	PU
Oneness re-announces the Board of Directors resolved to convene the Annual Shareholders' Meeting of 2022.(Method of convening the meeting: hybrid shareholders' meeting)	22-04-08	PU
Oneness Biotech : announces the information about the investor's conference of 2022 Q1.	22-03-25	PU
Oneness Biotech Co., Ltd. receives an Indonesian patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).	22-03-18	PU
Oneness Biotech : Nanchou manufacturing site received GMP certificate from the FDA Philippines	22-03-15	PU
Oneness Biotech : Announcement on the resignation of the Company's institutional director	22-03-07	PU
Oneness Biotech : The Malaysia National Pharmaceutical Regulatory Agency has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon	22-03-04	PU
Oneness Biotech : The mechanism of action, Phase 3 MRCT results and post-market cases of the DFU new drug, Fespixon have been accepted for an oral presentation at WUWHS 2022	22-03-01	PU
Oneness Biotech : Board of Directors resolved to convene the Annual Shareholders' Meeting of 2022.	22-02-25	PU
Oneness Biotech Co., Ltd. receives a Korean patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).	22-02-22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oneness Biotech Co., Ltd.

Equities

4743

TW0004743000

Press Releases

Filters